Telephone sharing button Contact Us mailbox sharing button
arrow_left sharing button
arrow_right sharing button

Press Releases

WuXi XDC and HKSTP Join Forces to Promote Development of Bioconjugate Drug Industry in Hong Kong
Oct. 18, 2023
WuXi XDC and HKSTP Join Forces to Promote Development of Bioconjugate Drug Industry in Hong Kong

1. WuXi XDC and Hong Kong Science and Technology Parks Corporation (HKSTPC) signed a cooperation framework agreement to jointly promote the establishment of a contract research, development and manufacturing organization(CRDMO) value chain in Hong Kong.


2. HKSTP Park companies will leverage WuXi XDC’s one-stop service platform to develop ADC and other bioconjugates.


3. WuXi XDC will support the development of the bioconjugation industry in Hong Kong by providing consultation and training to local enterprises.


SHANGHAI, October 18, 2023 – WuXi XDC, a leading global Contract, Research, Development, Manufacturing Organization (CRDMO) focused on the ADC and broader bioconjugate market, and Hong Kong Science and Technology Parks Corporation (HKSTP), signed a collaboration agreement to jointly advance the establishment of a CRDMO value chain in Hong Kong.
Photo: Dr Jimmy Li, CEO of WuXi XDC (fourth from left) and Dr Grace Lau, Head of Institute for Translational Research of HKSTP (fifth from left) signed a collaboration framework agreement.



The partnership will drive the development of ADC and other bioconjugates in Hong Kong leveraging WuXi XDC’s comprehensive services and capabilities. With the aim of boosting the biotechnology ecosystem in Hong Kong, both parties will enhance collaborations among industry, academic and research institutions.


HKSTP Park companies will have access to WuXi XDC’s integrated, one-stop bioconjugate platform for drug discovery, development, and analytical services. WuXi XDC will provide consultation and training to Hong Kong biotechnology companies and research institutions, accelerating the translation of the scientific research results into market-ready products.


HKSTPC and WuXi XDC will deepen the collaborations by sharing resources and organizing engagement activities. A roadmap will be set out for propelling the establishment of a CRDMO value chain in Hong Kong, which will in turn speed up the drug development process and shorten the time to market.


Dr. Jimmy Li, CEO of WuXi XDC, said, “We are pleased to collaborate with HKSTP in supporting local biotech companies with our one-stop platform, leading industry know-how and high-quality services. Hong Kong Science Park is a hotbed for biotechnology with innovation capabilities. We look forward to cementing our partnership with HKSTP, enabling the development of the bioconjugate industry and benefiting patients worldwide.”


Mr. Albert Wong, CEO of HKSTP, said, “As the largest technology research and development (R&D) base and incubator in Hong Kong, HKSTPC offers integrated state-of-the-art infrastructure and supporting services to the I&T ecosystem. We are excited to work with WuXi XDC to facilitate companies in terms of technology transfer and market expansion. By leveraging the strengths of both sides, we look forward to further enhancing the biotechnology ecosystem, paving the way for Hong Kong’s development into an international innovation and technology hub.”





About WuXi XDC


WuXi XDC is a leading global CRDMO focused on the ADC and broader bioconjugate market. It is a joint venture between WuXi Biologics and WuXi STA, providing end-to-end contract research, development and manufacturing services for bioconjugates, including antibody drug conjugates (ADCs). Its services cover antibody intermediates and other biologics intermediates, chemical payloads and linkers, as well as bioconjugate drug substances and drug products. WuXi XDC has been successful in bringing multiple ADC projects to the Investigational New Drug (IND) filing stage in 15 months or less, nearly cutting in half the traditional development timeline. As of June 2023, 110 on-going integrated projects are under development at WuXi XDC, including 47 post-IND bioconjugate projects, among which 16 projects are in phase II/III. For more information about WuXi XDC, please visit:


About Hong Kong Science and Technology Parks Corporation

Hong Kong Science and Technology Parks Corporation (HKSTP) has for over 20 years committed to building up Hong Kong as an international innovation and technology hub to propel success for local and global pioneers today and tomorrow. HKSTP has established a thriving I&T ecosystem that supported over 10 unicorns and Hong Kong’s leading R&D hub with over 13,000 research professionals and over 1,400 technology companies focused on healthtech, AI and robotics, fintech and smart city technologies.


Established in 2001, we attract and nurture talent, accelerate and commercialise innovation and technology for entrepreneurs on their journey of growth. Our growing innovation ecosystem is built around our key locations of Hong Kong Science Park in Shatin, InnoCentre in Kowloon Tong and three modern InnoParks in Tai Po, Tseung Kwan O and Yuen Long. The three InnoParks are realising a vision of new industrialisation for Hong Kong. The goal is sectors like advanced manufacturing, electronics and biotechnology are being reimagined for a new generation of industry.


Through our infrastructure, services, expertise, and network of partnerships, HKSTP will help establish innovation and technology as a pillar of growth for Hong Kong, while reinforcing Hong Kong’s international I&T hub status as a launchpad for growth at the heart of the GBA innovation powerhouse.


More information about HKSTP is available at









You are leaving WuXi Biologics Website, after which our Privacy Notice will not apply. Please keep it in mind the protection of your privacy. Are you willing to proceed?